Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Cyclic or irregular uterine bleeding is common in perimenarchal and perimenopausal women with or without endometrial hyperplasia. The disturbance often requires surgical treatment because of its negative effects on both blood loss and abnormal endometrial growth including the development of endometrial cancer. The endometrium is often overstimulated during the perimenopausal period when estrogen/progesterone production is unbalanced. A therapeutical approach with gonadotropin-releasing hormone agonist (GnRHa) was proposed in a depot formulation (Zoladex) that induces a sustained and reversible ovarian suppression. To avoid the risk of osteoporosis and to obtain adequate endometrial proliferation and differentiation during ovarian suppression, transdermal 17-beta-estradiol and oral progestin were administered. Results of 20 cases versus 20 controls showed a reduction of metrorrhagia, a normalization of hemoglobin plasma concentration, and an adequate proliferation and secretory differentiation of the endometrium of patients with abnormal endometrial growth. Abnormal uterine bleeding is mainly due to uterine fibrosis and an inadequate estrogen and/or progesterone production or to a disordered estrogen transport from blood into the endometrium. In premenopausal women, endometrial hyperplasia may be part of a continuum that is ultimately manifested in the histological and biological pattern of endometrial carcinoma. The regression of endometrial hyperplasia obtained by using the therapeutic regimen mentioned above represents a preventive measure for endometrial cancer. Finally the normalization of blood loss offers a good medical alternative to surgery for patients with DUB.
 ...
PMID:Dysfunctional uterine bleeding (DUB). 797 56

The LHRH analogues are used very much in gynecological practice, mostly for a long treatment periods. The menopausal side effects occur often and causes the patients to withdraw from treatment. The GnRh analogues are used for the treatment of endometriosis, uterine fibroids, for breast cancer, and pre and post operatively as hormonal therapy for endometrial cancer. 12 patients were given combined vaginal Ovestin and GnRh analogues (Zoladex). Another 12 patients were taking GnRh analogues alone without Ovestin creme, and this group searched as a control group. The group with the Ovestin had less side effects than the control group. This difference was statistically significant about the cervicovaginal symptoms (p less than 0.01). The treatment with vaginal estrogenes can better and improve the tolerance to therapy with GnRh analogues.
 ...
PMID:[The use of Ovestin to overcome the side effects of treatment with GnRH agonists (Zoladex)]. 1036 48

Six cases of primary treated endometrial cancer are included in this research work. Five of these women ended with tumour regression and 2 with pregnancies and deliveries of children. All of the women are still alive without having disease with mean follow-up period of 36.5 months (from 16 to 80 months). We consider that this is very promising method of treatment to offer y conservative treatment with high level of survival and possibility for having y child. Diagnostic and therapeutic data for the patients who are with early endometrial cancer and wish to have y child are analyised in this study. Four of the women were treated with GnRh-analogs-Zoladex and 2 with progestins-high doses.
 ...
PMID:[Primary hormone treatment of early endometrial cancer]. 1196 13

The discovery of hypothalamic hormones was briefly reviewed. The development of new hormonal methods for the therapy of various cancers based on analogues of hypothalmic hormones is then presented. My group isolated luteininzing hormone-releasing hormone (LH-RH), also known as Gn-RH, from pig hypothalmi, elucidated its amino acid sequence, and synthesized it in 1971. The interest in medical applications of LH-RH led to the synthesis of LH-RH analogues by various groups. LH-RH agonists substituted in positions 6 or 10 including Decapeptyl, Leuprolide and Zoladex are much more active than LH-RH and on continuous administration produce inhibition of pituitary and gonads. Chronic administration of LH-RH agonists is being utilized for the treatment of prostate and breast cancer. Octapeptide analogues of somatostatin have various applications in Oncology. In 1980 we developed a new endocrine therapy for advanced prostate cancer based on agonists of LH-RH, which is now preferred by 70-90% of prostate cancer patients for primary treatment. LH-RH antagonists such as Cetrorelix can be used for therapy of BPH. On the basis of the presence of specific receptors for hypothalamic peptides on human cancers, we developed targeted cytotoxic analogues of LH-RH, somatostatin, and bombesin/GRP linked to doxorubicin or 2-pyrrolinodoxorubicin. These analogues inhibit the growth of experimental human prostate, breast, ovarian and endometrial cancer, renal cell carcinoma, pancreatic, colorectal and gastric cancers, small cell lung carcinoma (SCLC) and non-SCLC, brain tumors, melanomas, and lymphomas. Cytotoxic LH-RH analogues are now in clinical trials. Recently we demonstrated that growth hormone-releasing hormone (GH-RH) also serves as an autocrine growth factor in many cancers. Antagonistic analogues of GH-RH synthesized in our laboratory inhibit the growth of diverse tumors. The discovery of LH-RH and somatostatin has led to clinical use of their analogues in the field of cancer treatment and GH-RH antagonists also show a great promise.
 ...
PMID:New approaches to the therapy of various tumors based on peptide analogues. 1849 Dec 50